Vikas Dudeja

8.7k total citations · 1 hit paper
169 papers, 6.3k citations indexed

About

Vikas Dudeja is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Vikas Dudeja has authored 169 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 62 papers in Molecular Biology and 49 papers in Surgery. Recurrent topics in Vikas Dudeja's work include Pancreatic and Hepatic Oncology Research (59 papers), Pancreatitis Pathology and Treatment (33 papers) and Natural Compounds in Disease Treatment (27 papers). Vikas Dudeja is often cited by papers focused on Pancreatic and Hepatic Oncology Research (59 papers), Pancreatitis Pathology and Treatment (33 papers) and Natural Compounds in Disease Treatment (27 papers). Vikas Dudeja collaborates with scholars based in United States, India and Egypt. Vikas Dudeja's co-authors include Ashok K. Saluja, Rajinder Dawra, Selwyn M. Vickers, Sulagna Banerjee, Phoebe A. Phillips, Rohit Chugh, Veena Sangwan, Raghuwansh P. Sah, Bhuwan Giri and Daniel Borja–Cacho and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Vikas Dudeja

163 papers receiving 6.2k citations

Hit Papers

Early Intra-Acinar Events in Pathogenesis of Pancreatitis 2019 2026 2021 2023 2019 50 100 150

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vikas Dudeja United States 46 2.7k 2.4k 1.8k 884 838 169 6.3k
Sushovan Guha United States 51 3.3k 1.2× 2.3k 1.0× 1.4k 0.8× 844 1.0× 225 0.3× 166 7.7k
Hongchi Jiang China 50 3.5k 1.3× 1.3k 0.5× 1.1k 0.6× 600 0.7× 197 0.2× 210 6.8k
Ashok K. Saluja United States 61 4.3k 1.6× 3.9k 1.6× 5.8k 3.2× 1.8k 2.0× 1.2k 1.5× 243 11.7k
Liang Cao China 44 4.0k 1.5× 2.1k 0.9× 320 0.2× 748 0.8× 463 0.6× 241 8.0k
Boon Cher Goh Singapore 53 4.2k 1.6× 3.1k 1.3× 585 0.3× 654 0.7× 243 0.3× 227 8.8k
Hassan Ashktorab United States 43 2.8k 1.0× 1.9k 0.8× 1.0k 0.6× 570 0.6× 101 0.1× 234 5.7k
Shangha Pan China 47 3.0k 1.1× 843 0.4× 556 0.3× 522 0.6× 197 0.2× 121 5.3k
Yoshiharu Motoo Japan 31 1.3k 0.5× 1.4k 0.6× 1.3k 0.7× 276 0.3× 250 0.3× 210 4.0k
Teresa Padró Spain 43 2.9k 1.1× 907 0.4× 1.5k 0.9× 1.1k 1.3× 108 0.1× 197 7.2k
Wenjie Guo China 36 2.2k 0.8× 839 0.4× 469 0.3× 1.1k 1.2× 600 0.7× 142 4.5k

Countries citing papers authored by Vikas Dudeja

Since Specialization
Citations

This map shows the geographic impact of Vikas Dudeja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikas Dudeja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikas Dudeja more than expected).

Fields of papers citing papers by Vikas Dudeja

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vikas Dudeja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikas Dudeja. The network helps show where Vikas Dudeja may publish in the future.

Co-authorship network of co-authors of Vikas Dudeja

This figure shows the co-authorship network connecting the top 25 collaborators of Vikas Dudeja. A scholar is included among the top collaborators of Vikas Dudeja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vikas Dudeja. Vikas Dudeja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
3.
Feng, Wendy, Ahmer Irfan, Vikas Dudeja, et al.. (2023). Understanding risk factors and microbial trends implicated in the development of Whipple-related surgical-site infections. SHILAP Revista de lepidopterología. 3(1). e36–e36.
4.
Irfan, Ahmer, et al.. (2023). What would you do? A survey of HPB surgeons practice patterns. HPB. 26(3). 436–443. 1 indexed citations
5.
Vickers, Selwyn M., et al.. (2023). Adjusting Drain Fluid Amylase for Drain Volume Does Not Improve Pancreatic Fistula Prediction. Journal of Surgical Research. 284. 312–317. 2 indexed citations
6.
Jain, Tejeshwar, Prateek Sharma, Bhuwan Giri, et al.. (2022). Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. HPB. 24(10). 1729–1737. 3 indexed citations
7.
George, John E., Mohammad Tarique, Tejeshwar Jain, et al.. (2022). Pirfenidone ameliorates chronic pancreatitis in mouse models through immune and cytokine modulation. Pancreatology. 22(5). 553–563. 14 indexed citations
8.
Irfan, Ahmer, Selwyn M. Vickers, Olumide B. Gbolahan, et al.. (2022). Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma?. The American Journal of Surgery. 224(3). 955–958. 2 indexed citations
9.
Jain, Tejeshwar & Vikas Dudeja. (2021). The war against pancreatic cancer in 2020 — advances on all fronts. Nature Reviews Gastroenterology & Hepatology. 18(2). 99–100. 50 indexed citations
10.
Jain, Tejeshwar, et al.. (2021). Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. International Journal of Molecular Sciences. 22(24). 13408–13408. 61 indexed citations
11.
George, John E., Mohammad Tarique, Bhuwan Giri, et al.. (2021). Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models. JCI Insight. 7(2). 26 indexed citations
12.
Garrido, Greta, Brett Schrand, Agata Levay, et al.. (2020). Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors. Cancer Immunology Research. 8(7). 856–868. 8 indexed citations
13.
Garrido, Greta, Brett Schrand, Ailem Rabasa, et al.. (2019). Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity. Nature Communications. 10(1). 3773–3773. 50 indexed citations
14.
Picado, Omar, et al.. (2018). Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta‐analysis. Journal of Surgical Oncology. 119(4). 455–463. 17 indexed citations
15.
Allen, Casey J., Danny Yakoub, Francisco Igor Macedo, et al.. (2018). Long-term Quality of Life and Gastrointestinal Functional Outcomes After Pancreaticoduodenectomy. Annals of Surgery. 268(4). 657–664. 39 indexed citations
16.
Dauer, Patricia, Xianda Zhao, Vineet K. Gupta, et al.. (2017). Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression. Cancer Research. 78(5). 1321–1333. 96 indexed citations
17.
Giri, Bhuwan, Vrishketan Sethi, Bharti Garg, et al.. (2017). “Heat shock protein 70 in pancreatic diseases: Friend or foe”. Journal of Surgical Oncology. 116(1). 114–122. 33 indexed citations
18.
Creasy, John M., Debra A. Goldman, Vikas Dudeja, et al.. (2017). Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. Journal of the American College of Surgeons. 224(5). 906–916. 53 indexed citations
19.
Banerjee, Sulagna, Shrey Modi, Olivia McGinn, et al.. (2015). Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer. Clinical Cancer Research. 22(2). 415–425. 90 indexed citations
20.
Banerjee, Sulagna, Alice Nomura, Veena Sangwan, et al.. (2014). CD133+ Tumor Initiating Cells in a Syngenic Murine Model of Pancreatic Cancer Respond to Minnelide. Clinical Cancer Research. 20(9). 2388–2399. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026